Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04727242 · ClinicalTrials.gov registry record · Phase 2
CytoreductiveSurgery & HIPEC w/Gemcitabine+Chemotherapy w/Dacarbazine in Uterine Leiomyosarcoma
A Phase 2 study of Uterine Leiomyosarcoma and LMS - Leiomyosarcoma, sponsored by Stanford University.
- Active
- Registry status
- Phase 2
- Development phase
- 17
- Enrollment target
- 1
- Study location
NCT04727242 is a Phase 2 study of Uterine Leiomyosarcoma and LMS - Leiomyosarcoma that is active but no longer recruiting, run by Stanford University. The registered enrollment target is 17 participants, below the 44-participant average among 3 other Uterine Leiomyosarcoma trials with a reported enrollment target (61% lower). The trial reports 1 study location across 1 state.
The verdict
NCT04727242, a Phase 2 study of Uterine Leiomyosarcoma and LMS - Leiomyosarcoma, is active but no longer recruiting, sponsored by Stanford University.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 17 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to find out if giving a dose of heated chemotherapy in the abdomen immediately after surgery that is done to remove uterine leiomyosarcoma type of cancer will help lower the risk of the cancer coming back in the future.
Conditions Studied
Interventions
- DRUG Gemcitabine
- PROCEDURE Cytoreductive Surgery
- DRUG Dacarbazine
- BEHAVIORAL Functional Assessment of Cancer Therapy (FACT) G questionnaire
- PROCEDURE Computed Tomography (CT) or Magnetic Resonance Imaging (MRI) Scan
Study Locations (1)
California
- Stanford University - Stanford
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 17 participants |
| Start Date | 2021-01-28 |
| Est. Completion | 2026-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04727242
The ClinicalTrials.gov registry entry for NCT04727242 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 17 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 44-participant average among 3 other Uterine Leiomyosarcoma trials with a reported enrollment target (61% lower). The listed sponsor is Stanford University, which has 1,744 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Uterine Leiomyosarcoma appearing as the primary indexed condition, and to 5 interventions - of which Gemcitabine is the first listed.
NCT04727242 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT04727242 about?
NCT04727242 is a clinical study titled "CytoreductiveSurgery & HIPEC w/Gemcitabine+Chemotherapy w/Dacarbazine in Uterine Leiomyosarcoma". The purpose of this study is to find out if giving a dose of heated chemotherapy in the abdomen immediately after surgery that is done to remove uterine leiomyosarcoma type of cancer will help lower the risk of the cancer coming back in the future.
What is the current status of trial NCT04727242?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 17 participants. The study started on 2021-01-28. Estimated completion is 2026-05.
What conditions does trial NCT04727242 study?
This clinical trial studies the following conditions: Uterine Leiomyosarcoma, LMS - Leiomyosarcoma.
What interventions are being tested in trial NCT04727242?
The interventions under investigation include: Gemcitabine (DRUG), Cytoreductive Surgery (PROCEDURE), Dacarbazine (DRUG), Functional Assessment of Cancer Therapy (FACT) G questionnaire (BEHAVIORAL), Computed Tomography (CT) or Magnetic Resonance Imaging (MRI) Scan (PROCEDURE).
Who is sponsoring clinical trial NCT04727242?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04727242 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Uterine Leiomyosarcoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.